The Necrotising Enterocolitis Treatment Market is driven by Rising Preterm Births
Neonatal necrotising enterocolitis (NEC) is a devastating gastrointestinal emergency that primarily affects premature infants. It is a disease caused by necrosis or dying of the intestine. The symptoms include abdominal distention, vomiting, and bloody stools. If not treated promptly, it can rapidly progress to sepsis, multi-organ failure, and even death.
NEC remains the most common gastrointestinal emergency affecting newborns, especially those born preterm. The exact cause of Necrotising Enterocolitis Market is unknown but prematurity plays a vital role. Other factors that increase the risk include formula feeding, bacterial colonization of the intestine, and an immature immune system in preterm infants.
Current treatment options include antibiotics, abdominal surgery such as bowel resection for severe disease, and TPN or total parenteral nutrition provided if oral feeding cannot be tolerated.
The Global Necrotising Enterocolitis Market is estimated to be valued at USD 7.10 Billion in 2024 and is expected to reach USD 10.41 Billion by 2031, growing at a compound annual growth rate (CAGR) of 5.6% from 2024 to 2031.
Key Takeaways
Key players operating in the neonatal necrotising enterocolitis treatment market are Medtronic, BD, B. Braun Melsungen AG, Danone Nutricia, and Chiesi Farmaceutici S.p.A.
The rising incidence of preterm births and low birth weight infants requiring NEC treatment is expected to drive the market during the forecast period. According to the World Health Organization, preterm birth complications are the leading cause of death among children under 5 years of age, with approximately 1 million children dying each year due to complications from preterm birth.
The market is also witnessing expansion in developing economies such as China, India, Brazil, and Mexico due to increasing awareness and improving healthcare infrastructure. This is expected to generate lucrative market opportunities globally.
Market Drivers
The key factor driving the growth of the neonatal necrotising enterocolitis treatment market is the rising preterm birth rates worldwide. According to the Centers for Disease Control and Prevention (CDC), 1 in 10 infants in the United States is born preterm resulting in rising predisposition to NEC. Other factors influencing the market growth include increasing healthcare expenditure, growth in the pediatric and neonatal patient pool, and rising initiatives by market players and governments.
The current geopolitical instability globally is impacting the growth of the Necrotising Enterocolitis market. With rising political tensions and conflicts in various parts of the world, there is increased migration of people within and across countries. This has led to a surge in the number of preterm births and low birth weight babies who are at higher risk of developing Necrotising Enterocolitis. The ongoing public health crisis has also overwhelmed healthcare systems in several nations, limiting adequate access to neonatal care.
To sustain growth, companies operating in the Necrotising Enterocolitis market need to focus on improving disease awareness and screening in unstable regions. Telemedicine can help bridge the gap and enable remote monitoring of at-risk infants. More research partnerships across borders will aid knowledge sharing and expediting of novel therapeutic development. Regional alliances must be forged to ensure uninterrupted supply of essential medical products and provisions for humanitarian relief. Overall, building resilient and adaptable supply chains through diverse sourcing and inventory strategies can help mitigate future unexpected demand fluctuations due to geopolitical issues.
Currently, North America accounts for the largest share of the global Necrotising Enterocolitis market in terms of value. This can be attributed to the rising preterm birth rates, presence of sophisticated healthcare infrastructure and growing adoption of advanced treatment options in the region. On the other hand, Asia Pacific is poised to witness the fastest growth over the forecast period owing to increasing healthcare spending, large patient pools and growing medical tourism in countries like India and China.
The Middle East region is concentrated with Necrotising Enterocolitis market value due to high incidence of preterm births associated with issues like maternal infections, diabetes, multiple pregnancies and malnutrition. Within the region, Gulf nations have seen a surge as they strive to provide world-class neonatal care facilities to cater to the large expat population. Meanwhile, Africa has the highest prematurity rates globally but remains underpenetrated due to lack of awareness and infrastructure challenges.
Get more insights on: Necrotising Enterocolitis Market
About Author: Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
English
Arabic
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian